ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Cardiovascular Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1523787

Triglyceride-Glucose Index as a Predictor of One-Year Mortality in Non-Diabetic Acute Ischemic Stroke

Provisionally accepted
  • 1Department of Neurology, Chongqing General Hospital, Chongqing, China
  • 2Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China
  • 3Laboratory of Epidemiology, Tianjin Neurological Institute, Tianjin, China
  • 4Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, China
  • 5Center of Clinical Epidemiology, Shenzhen Third People’s Hospital and the Second Hospital Affiliated with the Southern University of Science and Technology, Tianjin, China
  • 6Shenzhen Third People’s Hospital, Shenzhen, China
  • 7Department of Neurology, Shenzhen Third People’s Hospital and the Second Hospital Affiliated with the Southern University of Science and Technology, Tianjin, China

The final, formatted version of the article will be published soon.

AbstractBackground: Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality, and identifying reliable prognostic markers is crucial for improving outcomes. The triglyceride-glucose (TyG) index, a surrogate marker for insulin resistance, has been associated with adverse cardiovascular outcomes. However, its role in predicting stroke prognosis, particularly in non-diabetic patients, remains unclear. This study aimed to explore the association between the TyG index and one-year outcomes, including mortality, recurrence, and adverse functional outcomes, in non-diabetic IS patients.Methods: This prospective cohort study included AIS patients without diabetes from multiple hospitals. Baseline data, including the TyG index, were collected at admission, and patients were followed for one year. The primary outcomes were all-cause mortality, stroke recurrence, and adverse functional outcomes, defined as modified Rankin Scale (mRS) >2. Multivariate logistic regression and subgroup analyses were conducted to assess the predictive value of the TyG index for these outcomes.Results: Among the study population, 5.9% died within one year. The TyG index and its quartiles were significantly associated with one-year mortality, even after adjusting for confounding factors. Patients in the highest TyG quartile (Q4: TyG ≥ 8.9002) had a 3.72-fold higher risk of mortality compared to those in the lowest quartile (P = 0.013). Subgroup analysis showed that the TyG index was a stronger predictor of mortality in men and non-atrial fibrillation patients. Although the TyG index was not significantly associated with stroke recurrence or adverse functional outcomes in the overall cohort, it acted as a protective factor for recurrence in younger patients (< 65 years).Conclusion: The TyG index is an independent predictor of one-year mortality in non-diabetic IS patients and may aid in risk stratification, particularly in men and younger patients. Its potential role in predicting recurrence and functional outcomes warrants further investigation.

Keywords: Triglyceride-glucose index, ischemic stroke, Non-diabetic, Mortality, Recurrence

Received: 06 Nov 2024; Accepted: 05 May 2025.

Copyright: © 2025 Wang, Ning, Tu, Wang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yu Zhao, Shenzhen Third People’s Hospital, Shenzhen, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.